Heterocyclo substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors
AssigneePharmacia Corporation
InventorsJohn J. Talley, James A. Sikorski, Matthew J. Graneto, Jeffery S. Carter, Bryan H. Norman, Balekudru Devadas
Life of this patent
Estimating the term…
Abstract
This invention is in the field of antiinflammatory pharmaceutical agents and specifically relates to compounds, compositions and methods for treating disorders mediated by cyclooxygenase-2 or 5-lipoxygenase, such as inflammation.
Claims30
A compound of Formula I
- 32
- wherein A is a 5- or 6member ring substituent selected from partially unsaturated or unsaturated heterocyclo and carbocyclic rings, wherein A is optionally substituted, if possible, with a radical selected from acyl, halo, alkyl, haloalkyl, cyano, nitro, carboxyl, alkoxy, oxo, aminocarbonyl, alkoxycarbonyl, carboxyalkyl, cyanoalkyl, and hydroxyalkyl;
- wherein Y is one or more radicals selected from alkyl, alkynyl, alkenyl, aryl, aralkyl, cycloalkyl,
- wherein R1 is a substituent selected from heterocyclo, cycloalkyl, cycloalkenyl and aryl, wherein R1 is optionally substituted at a substitutable position with one or more radicals selected from alkyl, haloalkyl, cyano, carboxyl, alkoxycarbonyl, hydroxyl, hydroxyalkyl, haloalkoxy, amino, alkylamino, arylamino, nitro, alkoxyalkyl, alkylsulfinyl, halo, alkoxy and alkylthio;
- wherein R2 is selected from alkyl and amino;
- wherein R3 is a direct bond or a radical selected from
- 33
- wherein R4 is selected from hydrido,hydroxyl, alkyl, aryl, heterocyclo and cycloalkyl;
- wherein R5 is selected from hydrido, alkyl, aryl, heterocyclo and cycloalkyl;
- and
- wherein R6 is selected from hydrido and hydroxyl;
- provided R2 is amino when A is pyrazolyl;
- or a pharmaceutically-acceptable salt thereof.
A compound of Formula II
- 36
- wherein A is a ring substituent selected from thienyl, oxazolyl, furyl, pyrrolyl, thiazolyl, imidazolyl, isothiazolyl, isoxazolyl, pyrazolyl, cyclopentenyl, phenyl, and pyridyl;
- wherein A is optionally substituted, if possible, with a radical selected from acyl, halo, hydroxy, lower alkyl, lower haloalkyl, oxo, cyano, nitro, carboxyl, lower alkoxy, aminocarbonyl, lower alkoxycarbonyl, lower carboxyalkyl, lower cyanoalkyl, and lower hydroxyalkyl;
- wherein Y is lower alkyl;
- wherein R1 is a substituent selected from 5- and 6-membered heterocyclo, lower cycloalkyl, lower cycloalkenyl and aryl selected from phenyl, biphenyl and naphthyl, wherein R1 is optionally substituted at a substitutable position with one or more radicals selected from lower alkyl, lower haloalkyl, cyano, carboxyl, lower alkoxycarbonyl, hydroxyl, lower hydroxyalkyl, lower haloalkoxy, amino, lower alkylamino, phenylamino, nitro, lower alkoxyalkyl, lower alkylsulfinyl, halo, lower alkoxy and lower alkylthio;
- wherein R2 is selected from lower alkyl and amino;
- and wherein R5 is selected from hydrido, lower alkyl, phenyl, 5- and 6-membered heterocyclo and lower cycloalkyl;
- provided R2 is amino when A is pyrazolyl;
- or a pharmaceutically-acceptable salt thereof.
A compound of Formula III
- 37
- wherein A is a ring substituent selected from thienyl, oxazolyl, furyl, pyrrolyl, thiazolyl, imidazolyl, isothiazolyl, isoxazolyl, pyrazolyl, cyclopentyl, phenyl, and pyridyl;
- wherein A is optionally substituted, if possible, with a radical selected from acyl, halo, hydroxy, lower alkyl, lower haloalkyl, oxo, cyano, nitro, carboxyl, lower alkoxy, aminocarbonyl, lower alkoxycarbonyl, lower carboxyalkyl, lower cyanoalkyl, and lower hydroxyalkyl;
- wherein Y is a radical selected from lower alkyl;
- wherein R1 is a substituent selected from 5- and 6-membered heterocyclo, lower cycloalkyl, lower cycloalkenyl and aryl selected from phenyl, biphenyl and naphthyl, wherein R1 is optionally substituted at a substitutable position with one or more radicals selected from lower alkyl, lower haloalkyl, cyano, carboxyl, lower alkoxycarbonyl, hydroxyl, lower hydroxyalkyl, lower haloalkoxy, amino, lower alkylamino, phenylamino, nitro, lower alkoxyalkyl, lower alkylsulfinyl, halo, lower alkoxy and lower alkylthio;
- wherein R2 is selected from lower alkyl and amino;
- and wherein R5 is selected from hydrido and lower alkyl;
- or a pharmaceutically-acceptable salt thereof.
A pharmaceutical composition comprising a therapeutically-effective amount of a compound, said compound selected from a family of compounds of Formula I
- 38
- wherein A is a 5- or 6-member ring substituent selected from partially unsaturated or unsaturated heterocyclo and carbocyclic rings, wherein A is optionally substituted, if possible, with a radical selected from acyl, halo, alkyl, haloalkyl, cyano, nitro, carboxyl, alkoxy, oxo, aminocarbonyl, alkoxycarbonyl, carboxyalkyl, cyanoalkyl, and hydroxyalkyl;
- wherein Y is a radical selected from alkyl, alkynyl, alkenyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, 5- or 6-membered heterocyclo and heterocycloalkyl;
- wherein R1 is a substituent selected from heterocyclo, cycloalkyl, cycloalkenyl and aryl, wherein R1 is optionally substituted at a substitutable position with one or more radicals selected from alkyl, haloalkyl, cyano, carboxyl, alkoxycarbonyl, hydroxyl, hydroxyalkyl, haloalkoxy, amino, alkylamino, arylamino, nitro, alkoxyalkyl, alkylsulfinyl, halo, alkoxy and alkylthio;
- wherein R2 is selected from alkyl and amino;
- wherein R3 is a direct bond or a radical selected from
- 39
- wherein R4 is selected from hydrido, hydroxyl, alkyl, aryl, heterocyclo and cycloalkyl;
- wherein R5 is selected from hydrido, alkyl, aryl, heterocyclo and cycloalkyl;
- and
- wherein R6 is selected from hydrido and hydroxyl;
- provided R2 is amino, when A is pyrazolyl;
- or a pharmaceutically-acceptable salt thereof.
A pharmaceutical composition comprising a therapeutically-effective amount of a compound, said compound selected from a family of compounds of Formula II,
- 42
- wherein A is a ring substituent selected from thienyl, oxazolyl, furyl, pyrrolyl, thiazolyl, imidazolyl, isothiazolyl, isoxazolyl, pyrazolyl, cyclopentenyl, phenyl, and pyridyl;
- wherein A is optionally substituted, if possible, with a radical selected from acyl, halo, hydroxy, lower alkyl, lower haloalkyl, oxo, cyano, nitro, carboxyl, lower alkoxy, aminocarbonyl, lower alkoxycarbonyl, lower carboxyalkyl, lower cyanoalkyl, and lower hydroxyalkyl;
- wherein Y is lower alkyl;
- wherein R1 is a substituent selected from 5- and 6-membered heterocyclo, lower cycloalkyl, lower cycloalkenyl and aryl selected from phenyl, biphenyl and naphthyl, wherein R1 is optionally substituted at a substitutable position with one or more radicals selected from lower alkyl, lower haloalkyl, cyano, carboxyl, lower alkoxycarbonyl, hydroxyl, lower hydroxyalkyl, lower haloalkoxy, amino, lower alkylamino, phenylamino, nitro, lower alkoxyalkyl, lower alkylsulfinyl, halo, lower alkoxy and lower alkylthio;
- wherein R2 is selected from lower alkyl and amino;
- and wherein R5 is selected from hydrido, lower alkyl, phenyl, 5- and 6-membered heterocyclo and lower cycloalkyl;
- provided R2 is amino when A is pyrazolyl;
- or a pharmaceutically-acceptable salt thereof.
A pharmaceutical composition comprising a therapeutically-effective amount of a compound, said compound selected from a family of compounds of Formula III,
- 43
- wherein A is a ring substituent selected from thienyl, oxazolyl, furyl, pyrrolyl, thiazolyl, imidazolyl, isothiazolyl, isoxazolyl, pyrazolyl, cyclopentenyl, phenyl, and pyridyl;
- wherein A is optionally substituted, if possible, with a radical selected from acyl, halo, hydroxy, lower alkyl, lower haloalkyl, oxo, cyano, nitro, carboxyl, lower alkoxy, aminocarbonyl, lower alkoxycarbonyl, lower carboxyalkyl, lower cyanoalkyl, and lower hydroxyalkyl;
- wherein Y is a radical selected from lower alkyl;
- wherein R1 is a substituent selected from 5- and 6-membered heterocyclo, lower cycloalkyl, lower cycloalkenyl and aryl selected from phenyl, biphenyl and naphthyl, wherein R1 is optionally substituted at a substitutable position with one or more radicals selected from lower alkyl, lower haloalkyl, cyano, carboxyl, lower alkoxycarbonyl, hydroxyl, lower hydroxyalkyl, lower haloalkoxy, amino, lower alkylamino, phenylamino, nitro, lower alkoxyalkyl, lower alkylsulfinyl, halo, lower alkoxy and lower alkylthio;
- wherein R2 is selected from lower alkyl and amino;
- and wherein R5 is selected from hydrido and lower alkyl;
- or a pharmaceutically-acceptable salt thereof.
A method of treating a condition benefited by the inhibition of 5-lipoxygenase, cyclooxygenase-2 or both 5-lipoxygenase and cyclooxygenase-2, said method comprising administering to the subject having or susceptible to such inflammation or inflammation-associated disorder, a therapeutically-effective amount of a compound of Formula I
- 44
- wherein A is a 5- or 6-member ring substituent selected from partially unsaturated or unsaturated heterocyclo and carbocyclic rings, wherein A is optionally substituted, if possible, with a radical selected from acyl, halo, alkyl, haloalkyl, cyano, nitro, carboxyl, alkoxy, oxo, aminocarbonyl, alkoxycarbonyl, carboxyalkyl, cyanoalkyl, and hydroxyalkyl;
- wherein Y is a radical selected from alkyl, alkynyl, alkenyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, 5- or 6-membered heterocyclo and heterocycloalkyl;
- wherein R1 is a substituent selected from heterocyclo, cycloalkyl, cycloalkenyl and aryl, wherein R1 is optionally substituted at a substitutable position with one or more radicals selected from alkyl, haloalkyl, cyano, carboxyl, alkoxycarbonyl, hydroxyl, hydroxyalkyl, haloalkoxy, amino, alkylamino, arylamino, nitro, alkoxyalkyl, alkylsulfinyl halo, alkoxy and alkylthio;
- wherein R2 is selected from alkyl and amino;
- wherein R3 is a direct bond or a radical selected from
- 45
- wherein R4 is selected from hydrido, hydroxyl, alkyl, aryl, heterocyclo and cycloalkyl;
- wherein R5 is selected from hydrido, alkyl, aryl, heterocyclo and cycloalkyl;
- and
- wherein R6 is selected from hydrido and hydroxyl;
- provided R2 is amino when A is pyrazolyl;
- or a pharmaceutically-acceptable salt thereof.
A method of treating a condition benefited by the inhibition of 5-lipoxygenase, cyclooxygenase-2 or both 5-lipoxygenase and cyclooxygenase-2, said method comprising administering to the subject having or susceptible to such inflammation or inflammation-associated disorder, a therapeutically-effective amount of a compound of Formula II
- 48
- wherein A is a ring substituent selected from thienyl, oxazolyl, furyl, pyrrolyl, thiazolyl, imidazolyl, isothiazolyl, isoxazolyl, pyrazolyl, cyclopentenyl, phenyl and pyridyl;
- wherein A optionally substituted, if possible, with a radical selected from acyl, halo, hydroxy, lower alkyl lower haloalkyl, oxo, cyano, nitro, carboxyl, lower alkoxy, aminocarbonyl, lower alkoxycarbonyl, lower carboxyalkyl, lower cyanoalkyl, and lower hydroxyalkyl;
- wherein Y is lower alkyl;
- wherein R1 is a substituent selected from 5- and 6-membered heterocyclo, lower cycloalkyl, lower cycloalkenyl and aryl selected from phenyl, biphenyl and naphthyl, wherein R1 is optionally substituted at a substitutable position with one or more radicals selected from lower alkyl, lower haloalkyl, cyano, carboxyl, lower alkoxycarbonyl, hydroxyl, lower hydroxyalkyl, lower haloalkoxy, amino, lower alkylamino, phenylamino, nitro, lower alkoxyalkyl, lower alkylsulfinyl, halo, lower alkoxy and lower alkylthio;
- wherein R2 is selected from lower alkyl and amino;
- and wherein R5 is selected from hydrido, lower alkyl, phenyl, 5- and 6-membered heterocyclo and lower cycloalkyl;
- provided R2 is amino when A is pyrazolyl;
- or a pharmaceutically-acceptable salt thereof.
A method of treating a condition benefited by the inhibition of 5-lipoxygenase, cyclooxygenase-2 or both 5-lipoxygenase and cyclooxygenase-2, said method comprising administering to the subject having or susceptible to such inflammation or inflammation-associated disorder, a therapeutically-effective amount of a compound of Formula III
- 49
- wherein A is a ring substituent selected from thienyl, oxazolyl, furyl, pyrrolyl, thiazolyl, imidazolyl, isothiazolyl, isoxazolyl, pyrazolyl, cyclopentenyl, phenyl, and pyridyl;
- wherein A is optionally substituted, if possible, with a radical selected from acyl, halo, hydroxy, lower alkyl, lower haloalkyl, oxo, cyano, nitro, carboxyl, lower alkoxy, aminocarbonyl, lower alkoxycarbonyl, lower carboxyalkyl lower cyanoalkyl, and lower hydroxyalkyl;
- wherein Y is a radical selected from lower alkyl;
- wherein R1 is a substituent selected from 5- and 6-membered heterocyclo, lower cycloalkyl, lower cycloalkenyl and aryl selected from phenyl, biphenyl and naphthyl, wherein R1 is optionally substituted at a substitutable position with one or more radicals selected from lower alkyl, lower haloalkyl, cyano, carboxyl, lower alkoxycarbonyl, hydroxyl, lower hydroxyalkyl, lower haloalkoxy, amino, lower alkylamino, phenylamino, nitro, lower alkoxyalkyl lower alkylsulfinyl, halo, lower alkoxy and lower alkylthio;
- wherein R2 is selected from lower alkyl and amino;
- and wherein R5 is selected from hydrido and lower alkyl;
- or a pharmaceutically-acceptable salt thereof.
Dependencies are inferred from the claim text.